Schizophrenia typically manifests in late adolescence or early adulthood1 and is associated with reduced life expectancy, elevated risk of suicide2, serious physical illnesses3, and substantial health and social costs. Treatments are at least partially effective in most people, but many have chronic symptoms, and adverse treatment effects are common4. There is a need for novel therapeutic target discovery, a process impeded by our limited understanding of pathophysiology.
